Concepts (183)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Osteosarcoma | 5 | 2019 | 259 | 1.160 |
Why?
|
| Bone Neoplasms | 6 | 2023 | 428 | 1.160 |
Why?
|
| Rhabdomyosarcoma | 4 | 2025 | 208 | 1.090 |
Why?
|
| Rhabdomyosarcoma, Embryonal | 2 | 2023 | 52 | 0.930 |
Why?
|
| Mitotane | 1 | 2024 | 2 | 0.870 |
Why?
|
| Adrenocortical Carcinoma | 1 | 2024 | 11 | 0.860 |
Why?
|
| Adrenal Cortex Neoplasms | 1 | 2024 | 24 | 0.850 |
Why?
|
| Rhabdomyosarcoma, Alveolar | 1 | 2023 | 41 | 0.780 |
Why?
|
| Antineoplastic Agents, Hormonal | 1 | 2024 | 253 | 0.760 |
Why?
|
| Kasabach-Merritt Syndrome | 1 | 2022 | 9 | 0.740 |
Why?
|
| Hemangioendothelioma | 1 | 2022 | 24 | 0.730 |
Why?
|
| MicroRNAs | 3 | 2018 | 872 | 0.710 |
Why?
|
| Sarcoma, Kaposi | 1 | 2022 | 123 | 0.660 |
Why?
|
| Sarcoma, Ewing | 4 | 2023 | 111 | 0.640 |
Why?
|
| Neoplasms, Neuroepithelial | 1 | 2018 | 10 | 0.550 |
Why?
|
| Neoplasms | 6 | 2024 | 2855 | 0.540 |
Why?
|
| Kidney Neoplasms | 2 | 2020 | 437 | 0.530 |
Why?
|
| Retinal Neoplasms | 1 | 2018 | 68 | 0.520 |
Why?
|
| Wilms Tumor | 1 | 2018 | 116 | 0.500 |
Why?
|
| Sarcoma | 3 | 2025 | 205 | 0.500 |
Why?
|
| Exanthema | 1 | 2017 | 73 | 0.490 |
Why?
|
| Hepatoblastoma | 1 | 2018 | 186 | 0.460 |
Why?
|
| Lung Neoplasms | 6 | 2024 | 1493 | 0.440 |
Why?
|
| Skin | 1 | 2017 | 516 | 0.430 |
Why?
|
| Gene Expression Profiling | 2 | 2018 | 1753 | 0.410 |
Why?
|
| Biomarkers, Tumor | 3 | 2018 | 1560 | 0.400 |
Why?
|
| Oncologists | 2 | 2023 | 31 | 0.370 |
Why?
|
| Adolescent | 18 | 2025 | 20002 | 0.330 |
Why?
|
| Liver Neoplasms | 2 | 2018 | 1351 | 0.330 |
Why?
|
| Transcriptome | 1 | 2015 | 1052 | 0.280 |
Why?
|
| Humans | 31 | 2025 | 126753 | 0.250 |
Why?
|
| Child | 16 | 2025 | 25101 | 0.240 |
Why?
|
| Cyclophosphamide | 3 | 2023 | 421 | 0.240 |
Why?
|
| Appendiceal Neoplasms | 1 | 2025 | 21 | 0.230 |
Why?
|
| Young Adult | 9 | 2024 | 9665 | 0.230 |
Why?
|
| Colectomy | 1 | 2025 | 86 | 0.220 |
Why?
|
| Appendectomy | 1 | 2025 | 88 | 0.220 |
Why?
|
| Neuroendocrine Tumors | 1 | 2025 | 58 | 0.220 |
Why?
|
| Trophoblastic Tumor, Placental Site | 1 | 2024 | 1 | 0.210 |
Why?
|
| Bronchial Neoplasms | 1 | 2024 | 14 | 0.210 |
Why?
|
| Trophoblastic Neoplasms | 1 | 2024 | 5 | 0.210 |
Why?
|
| Gestational Trophoblastic Disease | 1 | 2024 | 9 | 0.210 |
Why?
|
| Carcinoid Tumor | 1 | 2024 | 24 | 0.210 |
Why?
|
| Chilblains | 1 | 2023 | 3 | 0.200 |
Why?
|
| Leuprolide | 1 | 2023 | 23 | 0.200 |
Why?
|
| Ovarian Reserve | 1 | 2023 | 11 | 0.200 |
Why?
|
| Lymph Nodes | 1 | 2025 | 373 | 0.190 |
Why?
|
| Uterine Neoplasms | 1 | 2024 | 103 | 0.190 |
Why?
|
| Female | 16 | 2025 | 68330 | 0.190 |
Why?
|
| Pneumonectomy | 1 | 2024 | 149 | 0.190 |
Why?
|
| Patient Participation | 2 | 2023 | 231 | 0.190 |
Why?
|
| Radiotherapy, Intensity-Modulated | 1 | 2022 | 94 | 0.180 |
Why?
|
| Decision Making | 2 | 2024 | 664 | 0.180 |
Why?
|
| Neoplasm Staging | 4 | 2025 | 1284 | 0.180 |
Why?
|
| Molecular Biology | 1 | 2022 | 68 | 0.180 |
Why?
|
| Medical Oncology | 1 | 2023 | 229 | 0.180 |
Why?
|
| Hormone Replacement Therapy | 1 | 2024 | 209 | 0.180 |
Why?
|
| Doxorubicin | 3 | 2023 | 286 | 0.170 |
Why?
|
| Physicians, Women | 1 | 2021 | 49 | 0.170 |
Why?
|
| Legislation, Drug | 1 | 2020 | 8 | 0.170 |
Why?
|
| Product Surveillance, Postmarketing | 1 | 2020 | 26 | 0.170 |
Why?
|
| Proton Therapy | 1 | 2022 | 151 | 0.170 |
Why?
|
| Pulmonary Artery | 1 | 2024 | 442 | 0.160 |
Why?
|
| Career Choice | 1 | 2021 | 158 | 0.160 |
Why?
|
| Pharmaceutical Preparations | 1 | 2020 | 80 | 0.160 |
Why?
|
| Soft Tissue Neoplasms | 1 | 2021 | 128 | 0.160 |
Why?
|
| Fertility Preservation | 1 | 2020 | 62 | 0.150 |
Why?
|
| Prognosis | 3 | 2018 | 4772 | 0.150 |
Why?
|
| Genomics | 3 | 2024 | 1546 | 0.150 |
Why?
|
| Chronic Disease | 1 | 2023 | 1194 | 0.140 |
Why?
|
| Endothelial Cells | 1 | 2022 | 501 | 0.140 |
Why?
|
| Epigenomics | 1 | 2019 | 173 | 0.140 |
Why?
|
| Male | 12 | 2025 | 62543 | 0.140 |
Why?
|
| Drug-Related Side Effects and Adverse Reactions | 1 | 2020 | 259 | 0.140 |
Why?
|
| Blueberry Plants | 1 | 2017 | 6 | 0.130 |
Why?
|
| GTPase-Activating Proteins | 1 | 2017 | 85 | 0.130 |
Why?
|
| Clinical Trials as Topic | 1 | 2021 | 1102 | 0.130 |
Why?
|
| Parents | 1 | 2024 | 1072 | 0.130 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2023 | 1234 | 0.130 |
Why?
|
| Attitude of Health Personnel | 1 | 2021 | 694 | 0.120 |
Why?
|
| Sarcoma, Experimental | 1 | 2015 | 15 | 0.120 |
Why?
|
| Real-Time Polymerase Chain Reaction | 1 | 2018 | 523 | 0.120 |
Why?
|
| Child, Preschool | 5 | 2025 | 14347 | 0.120 |
Why?
|
| Tumor Suppressor Protein p53 | 2 | 2019 | 726 | 0.110 |
Why?
|
| Apoptosis Regulatory Proteins | 1 | 2015 | 161 | 0.110 |
Why?
|
| Allografts | 1 | 2015 | 189 | 0.110 |
Why?
|
| Proto-Oncogene Proteins c-myc | 1 | 2015 | 193 | 0.110 |
Why?
|
| ROC Curve | 1 | 2015 | 587 | 0.100 |
Why?
|
| RNA, Long Noncoding | 1 | 2015 | 228 | 0.100 |
Why?
|
| Vincristine | 2 | 2023 | 190 | 0.090 |
Why?
|
| Adult | 7 | 2024 | 30410 | 0.090 |
Why?
|
| Diagnosis, Differential | 1 | 2017 | 1861 | 0.090 |
Why?
|
| Neoplasm Metastasis | 3 | 2018 | 686 | 0.080 |
Why?
|
| Survival Rate | 3 | 2024 | 2101 | 0.080 |
Why?
|
| Gene Expression Regulation, Neoplastic | 1 | 2017 | 1931 | 0.080 |
Why?
|
| Retrospective Studies | 6 | 2025 | 17005 | 0.080 |
Why?
|
| Etoposide | 2 | 2023 | 109 | 0.080 |
Why?
|
| Neuroblastoma | 1 | 2014 | 539 | 0.080 |
Why?
|
| Pediatrics | 1 | 2018 | 1202 | 0.070 |
Why?
|
| Surveys and Questionnaires | 3 | 2024 | 3907 | 0.070 |
Why?
|
| Reproducibility of Results | 1 | 2015 | 2883 | 0.070 |
Why?
|
| Infant | 3 | 2018 | 12771 | 0.070 |
Why?
|
| Mice, Knockout | 1 | 2015 | 3709 | 0.070 |
Why?
|
| United States | 4 | 2025 | 11310 | 0.060 |
Why?
|
| Follow-Up Studies | 1 | 2015 | 5114 | 0.060 |
Why?
|
| Margins of Excision | 1 | 2025 | 56 | 0.060 |
Why?
|
| Xenograft Model Antitumor Assays | 2 | 2018 | 946 | 0.060 |
Why?
|
| Disease Models, Animal | 1 | 2015 | 4429 | 0.050 |
Why?
|
| Mice | 3 | 2017 | 17596 | 0.050 |
Why?
|
| Infant, Newborn | 1 | 2017 | 8347 | 0.050 |
Why?
|
| Disease-Free Survival | 2 | 2017 | 898 | 0.050 |
Why?
|
| Europe | 1 | 2025 | 359 | 0.050 |
Why?
|
| Lymphatic Metastasis | 1 | 2025 | 424 | 0.050 |
Why?
|
| Cysts | 1 | 2024 | 89 | 0.050 |
Why?
|
| Survivorship | 1 | 2023 | 46 | 0.050 |
Why?
|
| Erythema | 1 | 2023 | 27 | 0.050 |
Why?
|
| Aneurysm, False | 1 | 2024 | 84 | 0.050 |
Why?
|
| Anti-Mullerian Hormone | 1 | 2023 | 43 | 0.050 |
Why?
|
| Radiotherapy Planning, Computer-Assisted | 1 | 2022 | 76 | 0.050 |
Why?
|
| Protons | 1 | 2022 | 98 | 0.050 |
Why?
|
| Radiotherapy Dosage | 1 | 2022 | 194 | 0.050 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 2 | 2023 | 1302 | 0.050 |
Why?
|
| Cross-Sectional Studies | 2 | 2021 | 3662 | 0.050 |
Why?
|
| Gene Fusion | 1 | 2022 | 59 | 0.040 |
Why?
|
| Counseling | 1 | 2023 | 233 | 0.040 |
Why?
|
| Ovary | 1 | 2024 | 358 | 0.040 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2024 | 1048 | 0.040 |
Why?
|
| Pregnancy | 2 | 2024 | 7373 | 0.040 |
Why?
|
| Government Regulation | 1 | 2020 | 43 | 0.040 |
Why?
|
| Survivors | 1 | 2023 | 345 | 0.040 |
Why?
|
| Animals | 3 | 2017 | 33051 | 0.040 |
Why?
|
| United States Food and Drug Administration | 1 | 2020 | 149 | 0.040 |
Why?
|
| Lung Diseases | 1 | 2024 | 395 | 0.040 |
Why?
|
| Apoptosis | 2 | 2017 | 1811 | 0.040 |
Why?
|
| Placenta | 1 | 2024 | 511 | 0.040 |
Why?
|
| Risk Factors | 2 | 2023 | 10555 | 0.040 |
Why?
|
| Fertility | 1 | 2020 | 251 | 0.030 |
Why?
|
| Health Knowledge, Attitudes, Practice | 1 | 2024 | 880 | 0.030 |
Why?
|
| cdc42 GTP-Binding Protein | 1 | 2017 | 32 | 0.030 |
Why?
|
| Genetic Testing | 1 | 2024 | 1056 | 0.030 |
Why?
|
| Feedback, Physiological | 1 | 2017 | 67 | 0.030 |
Why?
|
| p21-Activated Kinases | 1 | 2017 | 54 | 0.030 |
Why?
|
| Transcription Factor AP-1 | 1 | 2017 | 107 | 0.030 |
Why?
|
| Mice, Inbred NOD | 1 | 2017 | 289 | 0.030 |
Why?
|
| Mice, SCID | 1 | 2017 | 568 | 0.030 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2024 | 2039 | 0.030 |
Why?
|
| Epithelial-Mesenchymal Transition | 1 | 2017 | 235 | 0.030 |
Why?
|
| Tumor Cells, Cultured | 1 | 2017 | 985 | 0.030 |
Why?
|
| Caspase 2 | 1 | 2015 | 27 | 0.030 |
Why?
|
| Primary Cell Culture | 1 | 2015 | 103 | 0.030 |
Why?
|
| Proteomics | 1 | 2019 | 562 | 0.030 |
Why?
|
| Karyotyping | 1 | 2015 | 312 | 0.030 |
Why?
|
| Consolidation Chemotherapy | 1 | 2014 | 6 | 0.030 |
Why?
|
| 3-Iodobenzylguanidine | 1 | 2014 | 12 | 0.030 |
Why?
|
| Gene Amplification | 1 | 2015 | 227 | 0.030 |
Why?
|
| Lung | 1 | 2022 | 1516 | 0.030 |
Why?
|
| Radionuclide Imaging | 1 | 2014 | 122 | 0.030 |
Why?
|
| Carboplatin | 1 | 2014 | 77 | 0.030 |
Why?
|
| Osteoblasts | 1 | 2015 | 160 | 0.030 |
Why?
|
| Aged | 2 | 2023 | 20344 | 0.030 |
Why?
|
| Induction Chemotherapy | 1 | 2014 | 54 | 0.030 |
Why?
|
| Genetic Loci | 1 | 2015 | 342 | 0.030 |
Why?
|
| Neoplasm, Residual | 1 | 2014 | 131 | 0.030 |
Why?
|
| Radiopharmaceuticals | 1 | 2014 | 159 | 0.030 |
Why?
|
| Genomic Instability | 1 | 2015 | 239 | 0.030 |
Why?
|
| In Situ Hybridization, Fluorescence | 1 | 2015 | 748 | 0.030 |
Why?
|
| Cell Movement | 1 | 2017 | 849 | 0.030 |
Why?
|
| Homozygote | 1 | 2015 | 540 | 0.030 |
Why?
|
| Quality of Life | 1 | 2023 | 2029 | 0.020 |
Why?
|
| Cisplatin | 1 | 2014 | 269 | 0.020 |
Why?
|
| Up-Regulation | 1 | 2015 | 824 | 0.020 |
Why?
|
| Risk Assessment | 1 | 2022 | 3586 | 0.020 |
Why?
|
| Chromosome Deletion | 1 | 2015 | 642 | 0.020 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 1 | 2015 | 999 | 0.020 |
Why?
|
| Mutation, Missense | 1 | 2015 | 891 | 0.020 |
Why?
|
| Cell Proliferation | 1 | 2017 | 2397 | 0.020 |
Why?
|
| Mice, Transgenic | 1 | 2015 | 2310 | 0.020 |
Why?
|
| Treatment Outcome | 1 | 2023 | 12546 | 0.020 |
Why?
|
| Mice, Inbred C57BL | 1 | 2015 | 4504 | 0.020 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 1 | 2014 | 1170 | 0.020 |
Why?
|
| Mutation | 1 | 2019 | 5941 | 0.010 |
Why?
|
| Signal Transduction | 1 | 2017 | 4472 | 0.010 |
Why?
|
| Middle Aged | 1 | 2021 | 27697 | 0.010 |
Why?
|